CtrlK
Cadrenal Therapeutics
CVKD42
$16.82arrow_drop_down6.14%-$1.08
CVKD42
$16.82
arrow_drop_down6.14%Performance History
There's no data available for performance history chart
| Key Stats | |
|---|---|
| Open | $16.85 |
| Prev. Close | $17.67 |
| EPS | -6.73 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $31.61M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 16.62 | 18.19 |
| 52 Week Range | 5.40 | 32.55 |
| Ratios | |
|---|---|
| P/B Ratio | 9.92 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | $0.00 |
| Earnings Growth % | -24.47% |
| EBITDA Margin % | - |
| ROE % | -125.15% |
| EPS | -6.73 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Predicted: just now
info
Analyzed by 27 Wall Street experts, Northern Trust's 12-month projections average at $86.00, spanning from a high of $103.00 to a low of $71.00. This signifies an -5.05% shift from the current price of $90.58.
Analyst Ratings
Hold
| Buy | 2 | 13.33% | |
|---|---|---|---|
| Hold | 11 | 73.33% | |
| Sell | 2 | 13.33% |
•Ratings from: April•
Last updated: just now
•Total: 15info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.
About Cadrenal Therapeutics (CVKD)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Quang X. Pham
- Headquarters
- Ponte Vedra
- Employees
- 3
- Exchange
- NASDAQ
Keep an eye on Cadrenal Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Cadrenal Therapeutics's (CVKD) price per share?
The current price per share for Cadrenal Therapeutics (CVKD) is $16.82. The stock has seen a price change of -$1.09 recently, indicating a -6.14% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Cadrenal Therapeutics (CVKD)?
For Cadrenal Therapeutics (CVKD), the 52-week high is $32.55, which is 93.52% from the current price. The 52-week low is $5.4, the current price is 211.48% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Cadrenal Therapeutics (CVKD) a growth stock?
Cadrenal Therapeutics (CVKD) has shown an average price growth of -1.65% over the past three years. It has received a score of 99 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cadrenal Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Cadrenal Therapeutics (CVKD) stock price performance year to date (YTD)?
As of the latest data, Cadrenal Therapeutics (CVKD) has a year-to-date price change of 16.08%. Over the past month, the stock has experienced a price change of -3.33%. Over the last three months, the change has been 6.12%. Over the past six months, the figure is 47.54%.
help
Is Cadrenal Therapeutics (CVKD) a profitable company?
Cadrenal Therapeutics (CVKD) has a net income of -$8.36M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$7.63M. Furthermore, the EBITDA is -$7.94M.
help
What is the market capitalization of Cadrenal Therapeutics (CVKD)?
Cadrenal Therapeutics (CVKD) has a market capitalization of $31.62M. The average daily trading volume is 17.39, indicating the stock's liquidity and investor engagement.